BioWorld

Aug. 28, 2008

View Archived Issues

Direct Reprogramming Is New Cell Source for Regeneration

Read More

NexMed Shares Fall Hard as Novartis Nixes NDA

Read More

Other News To Note

Read More

Clinic Roundup

Read More

Cell Genesys Falls 70% as Patient Deaths Derail GVAX Phase III

In yet another setback for cancer vaccines, Cell Genesys Inc. terminated one of its two Phase III trials with prostate cancer vaccine GVAX. (BioWorld Today) Read More

Amylin Sinks on Further Byetta Worries: More Deaths Reported

Read More